Anyone really think that a potential patient popul

Quote:

---

Anyone really think that a potential patient population of 300k or more would really warrant a mere 15 million bucks for a deal for a drug that prevents a severe side effect like oral mucositis?

---

I don't think anyone here thinks that. I said >$15M upfront + phase 3 trial cost . A phase 3 is what? $10M-$50M?

Quote:

---

If we sign a deal with >$15M upfront + a phase 3 cost - definitely.

---

Clarified again for Sox in a later post:

Quote:

---

$15M upfront + phase 3 trial costs in addition to milestones and royalties

---

I thought the consensus here was that this is going to be a royalty company. You minimize upfront to maximize the back end payments.

This is inline with what some other investors more knowledgeable than myself think. Here's BioHedge's take:

https://investorshub.advfn.com/boards/read_ms...=138082418

A deal like that would send the stock well above $2. A 200%+ gain over night.

Regardless, this whole conjecture was a response to NotRichYet2's question about whether 2018 is the year IPIX. I believe we will hit both of the targets I proposed and if we do, IPIX will hit new highs by the end of the year.

Go IPIX!

All my posts are my own personal opinion and speculation. They should not be used as the basis for any investment decision. No, I am not Scottsmith.